All In Biotech

Drug Trial Radar · NCT07114601

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

421

Planned (sponsor's estimate)

Start

Aug 6, 2025

Primary completion

Apr 2030

Study completion Apr 2035

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Aug 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.

Conditions

  • Breast Neoplasms
  • Colorectal Neoplasms
  • Prostate Neoplasm
  • Endometrial Neoplasms
  • Neoplasm Metastasis
  • Stomach Neoplasms
  • Esophageal Neoplasms

Interventions

  • LY4257496Drug

    Administered IV

  • Standard of Care Anticancer TherapiesDrug

    Fulvestrant, Imlunestrant, Aromatase Inhibitors, Capecitabine, Abemaciclib

  • LY4257529Diagnostic test

    Administered IV at select sites

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496Time frame: From Cycle 1 Day 1 (C1D1) through 28 days after the first dose of study drug. Cycle = 28 days
  2. Phase 1a Dose Optimization: Number of Dose Limiting Toxicities of LY4257496Time frame: From Cycle 1 Day 1 (C1D1) through 28 days after the first dose of study drug. Cycle = 28 days
  3. Phase 1b Dose Expansion and Optimization: Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)Time frame: From C1D1 through efficacy follow-up, estimated as Week 42. Cycle = 42 weeks

Locations

33 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • University of California, Los Angeles (UCLA)

    Santa Monica, California · Recruiting

  • Stanford University Medical Center

    Stanford, California · Recruiting

  • Biogenix Molecular, LLC

    Miami, Florida · Active not recruiting

  • Moffitt

    Tampa, Florida · Recruiting

  • Emory University School of Medicine - Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Not yet recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • BAMF Health Inc.

    Grand Rapids, Michigan · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • New York University (NYU) Langone Medical Center

    New York, New York · Not yet recruiting

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Texas Oncology - DFW (Sammons CC)

    Dallas, Texas · Not yet recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Juravinski Cancer Centre

    Hamilton, Canada · Recruiting

  • Lady Davis Institute for Medical Research Jewish General Hospital

    Montreal, Canada · Not yet recruiting

  • Sunnybrook Health Sciences Centre

    Toronto, Canada · Recruiting

  • Princess Margaret Hospital

    Toronto, Canada · Recruiting

  • Peking Union Medical College Hospital of Chinese Academy of Medical Sciences

    Beijing, China · Not yet recruiting

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, China · Not yet recruiting

  • Institut Curie

    Paris, France · Not yet recruiting

  • Institut de Cancerologie de l'Ouest - site St-Herblain

    Saint-Herblain, France · Not yet recruiting

  • Universitaetsklinikum Erlangen

    Erlangen, Germany · Not yet recruiting

  • Universitaetsklinikum Essen

    Essen, Germany · Recruiting

  • LMU Klinikum Muenchen-Campus Grosshadern

    München, Germany · Not yet recruiting

  • Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

    München, Germany · Not yet recruiting

  • National Cancer Center Hospital East

    Chiba, Japan · Not yet recruiting

  • Kyoto University Hospital

    Kyoto, Japan · Not yet recruiting

  • The University of Osaka Hospital

    Osaka, Japan · Not yet recruiting

  • Hospital Universitari Quiron Dexeus Barcelona

    Barcelona, Spain · Not yet recruiting

  • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

    Madrid, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.